Home

  • Events
  • Site Search
  • Join Us
  • About Us
    • Mission
    • History
    • People
      • Board of Directors
      • Leadership and Staff
      • Advisory Board
      • Senior Fellows
      • International Advisors
    • Contact Us
  • Research & education
    • IP Competition Project
    • Working Papers
    • Education and Film
    • Compliance Training
    • Publications
    • Judicial Education Program
    • Jury Instruction Project
  • Advocacy
    • Amicus Program
    • Commentaries
    • Testimony and Interventions
    • White Papers
  • Industries
    • Airlines
    • Food and Agriculture
    • Energy
    • Health and Pharma
    • IP and Innovation
    • Retail and Distribution
    • Technology and Communications
    • Transportation
  • Reports
    • National Competition Policy
    • Presidential Transition Report
    • Entrepreneurship Report
  • Events & Awards
    • Upcoming Events
    • Past Events
  • Media
  • Support
    • Donate
    • AAI Sponsors
    • Sherman Society

About AAI

The American Antitrust Institute is an independent, nonprofit organization devoted to promoting competition that protects consumers, businesses, and society. We serve the public through research, education, and advocacy on the benefits of competition and the use of antitrust enforcement as a vital component of national and international competition policy. 

more

Join Us

Latest News

03-26-2018 - AAI Calls on DOJ to Block the Merger of CVS-Aetna — Vertical Integration Will Restructure Important Healthcare Markets, to the Detriment of Competition and Consumers

In a letter to the U.S. Department of Justice, the American Antitrust Institute (AAI) called on the agency to block the proposed merger of retail pharmacy and PBM giant CVS and Big 5 health insurer Aetna. CVS-Aetna would pair up the largest retail pharmacy chain and one of the two largest PBMs with the third largest health insurer in the U.S. The proposed merger raises a number of questions for competition and consumers. The AAI letter focuses on the merger’s potential to enhance the incentive of CVS-Aetna to exclude rivals and facilitate anticompetitive coordination among health insurers served by PBM CVS-Caremark. CVS and Aetna already wield significant market power in the retail pharmacy, PBM, and health insurance markets. High concentration in these markets exacerbates competitive concerns. Market idiosyncrasies heighten the proposed merger’s potentially anticompetitive effects. These include the role of health insurers in paying for most prescriptions filled and of PBMs in managing the flow of prescription drugs to millions of Americans, and PBM markets that lack important transparency.

04-09-2018 - AAI Highlights Need to Realign Merger Remedies With the Goals of Antitrust

In a white paper released today “Realigning Merger Remedies with the Goals of Antitrust,” the American Antitrust Institute makes the case for why remedies policy may be at an important inflection point. The paper notes that we do not yet know the full extent to which rising concentration, slowing rates of startups, and widening inequality gaps are the product of the lax antitrust enforcement that has prevailed in U.S. for three decades. But as the story continues to unfold, it remains clear that merger enforcement should be high on the antitrust agenda. 

04-09-2018 - Speaker Line Up Announced for AAI Annual Conference

2018 marks the American Antitrust Institute’s 20th anniversary as the leading independent, nonprofit organization devoted to promoting competition that protects consumers, businesses, and society. In celebration of this important milestone, on Thursday, June 21, 2018, the American Antitrust Institute will host its 19th Annual Conference “Antitrust at a Crossroads: Plotting the Policy Course for the Next Decade.”

View All

Upcoming Events

  • Jun 21
    19th Annual Conference "Antitrust at a Crossroads - Plotting the Course for the Next Decade"
  • Nov 14
    12th Annual Private Antitrust Enforcement Conference
view all
Home>DOJ

DOJ

AAI, FWW, and NFU Say Monsanto-Bayer Merger Raises Competitive Concerns Over Traits-Seeds-Chemicals Platforms, Digital Farming, and Strategic Competitive Use of Farm Data
Oct 03 2017
White Papers
DOJ, Food and Agriculture, IP and Innovation, Mergers and Joint Ventures
American Antitrust Institute, Food & Water Watch, and National Farmers Union Say Monsanto-Bayer Merger Puts Competition, Farmers, and Consumers at Risk
Jul 26 2017
White Papers
DOJ, Food and Agriculture, IP and Innovation, Mergers and Joint Ventures
Antitrust and Inequality: What Antitrust Can and Should Do to Protect Workers
Apr 25 2017
Diana Moss
Commentaries
DOJ, Entrepreneurship, FTC, IP and Innovation, Mergers and Joint Ventures
AAI Files Comments on Agencies' Proposed Update of International Antitrust Guidelines
Dec 01 2016
Richard Brunell
Randy Stutz
Testimony and Interventions
DOJ, FTC, International
AAI Says DOJ’s Actions in Beer and Health Insurance are Essential Steps in Antitrust Enforcement
Jul 21 2016
AAI Announcements
DOJ, Health and Pharma, Mergers and Joint Ventures
AAI Says Effective Remedy in AB InBev-SABMiller is a Tall Order
Apr 25 2016
Diana Moss
Testimony and Interventions
DOJ, Mergers and Joint Ventures, Monopolies, Retail and Distribution

Site Search

Advanced Search >

ADDRESS:
1025 Connecticut Avenue, NW
Suite 1000
Washington, DC  20036

 

  • About Us
  • Terms of Use
  • People
  • Support the aai
  • Contact Us

Copyright © American Antitrust Institute 2018